Nordin H, Galløe A M, Ladefoged S D, Badskjaer J
Medical Department, Sundby Hospital, University of Copenhagen, Denmark.
Acta Endocrinol (Copenh). 1993 Apr;128(4):297-300. doi: 10.1530/acta.0.1280297.
The effects of acute and chronic administration of propranolol and verapamil on heart rate and systolic time intervals were studied in 10 hyperthyroid patients and 10 normal subjects, both groups without signs of cardiovascular or pulmonary disease. In normal subjects iv propranolol reduced heart rate significantly, and both drugs increased the total electromechanical systole significantly without difference between the drugs. This effect was insignificant when the drugs were given orally. In hyperthyroid patients both drugs reduced heart rate significantly in acute and chronic administration, and no difference between the two drugs was found. Neither drug altered cardiac contractility as assessed by systolic time intervals. These results indicate that the metabolic effects of thyroid hormone on contractility were unaltered and unblocked by the drugs. None of the participants developed signs of heart failure. Verapamil can thus be used as an alternative to propranolol in the treatment of tachycardia in hyperthyroidism.
在10名甲状腺功能亢进患者和10名正常受试者中研究了急性和慢性给予普萘洛尔和维拉帕米对心率和收缩期时间间期的影响，两组均无心血管或肺部疾病体征。在正常受试者中，静脉注射普萘洛尔可显著降低心率，两种药物均可显著增加总电机械收缩期，且两种药物之间无差异。口服给药时，这种效应不显著。在甲状腺功能亢进患者中，急性和慢性给药时两种药物均可显著降低心率，且两种药物之间无差异。两种药物均未改变通过收缩期时间间期评估的心脏收缩力。这些结果表明，甲状腺激素对收缩力的代谢作用未被药物改变和阻断。所有参与者均未出现心力衰竭体征。因此，维拉帕米可作为普萘洛尔的替代品用于治疗甲状腺功能亢进中的心动过速。
